The functional role of tumor suppressor genes in gliomas: Clues for future therapeutic strategies

Neurology

Volumn 51, Issue 5, 1998, Pages 1250-1255

  Fueyo, Juan ^a   Gomez Manzano, Candelaria ^a   Yung, W K Alfred ^a   Kyritsis, Athanassios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

CANCER CELL; CANCER RESEARCH; CELL GROWTH; CHROMOSOME 10; FAMILIAL CANCER; GENE TRANSFER; GLIOMA; NERVE CELL NECROSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0031798246     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.5.1250     Document Type: Review

References (49)

1. Harris H, Miller OJ, Klein G, et al. Suppression of malignancy by cell fusion. Nature 1969;223:363-368.
2. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823.
3. Fearon ER. Tumor suppressor genes. In: Volgestein B, Kinzler KW, eds. The genetic basis of human cancer. New York: McGraw-Hill, 1998:229-236.
4. Weinberg RA. E2F and cell proliferation: a world turned upside down. Cell 1996;85:457-459.
5. Haber D, Harlow E. Tumor-suppressor genes: evolving definitions in the genomic age. Nat Genet 1997;16:320-322.
6. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-28.
7. Collins VP, James CD. Gene and chromosomal alterations associated with the development of human gliomas. FASEB J 1993;7:926-930.
8. James CD, Collins PV. Glial tumors. In: Levine AJ, Schmidek HH, eds. Molecular genetics of nervous system tumors. New York: Wiley-Liss, 1993:241-248.
9. Furnari FB, Huang HJ, Cavenee WK. Genetics and malignant progression of human brain tumours. Cancer Surv 1995;25: 233-275.
10. Kleihues P, Ohgaki H. Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol 1997;7:1131-1136.
11. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
12. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-556.
13. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352: 345-347.
14. Lavigueur A, Maltby V, Mock D, et al. High incidence of lung, bone and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 1989;9: 3982-3991.
15. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-1455.
16. Nigro JM, Baker SJ, Preisinger AC. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342: 705-708.
17. Frankel RH, Bayona W, Koslow M, Newcomb EW. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 1992;52: 1427-1433.
18. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawtnon RM. p53 mutations and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 1992;52:674-679.
19. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavenee W, Volgestein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992;355:846-847.
20. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1933-1938.
21. Kyritsis AP, Bondy ML, Xiao M, et al. Germ line p53 gene mutations in subsets of glioma patients. J Natl Cancer Inst 1994;86:344-349.
22. Mercer WE, Shields MT, Amin M, et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 1990;87:6166-6170.
23. Rosenfeld MR, Meneses P, Dalmau J, Drobjnak M, Cordon-Cardo C, Kaplitt MG. Gene transfer of wild-type p53 results in restoration of tumor suppressor function in a medulloblastoma cell line. Neurology 1994;45:1533-1539.
24. Van Meir EG, Roemer K, Diserens A-C, et al. Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. Proc Natl Acad Sci USA 1995;92:1008-1012.
25. Gomez-Manzano C, Fueyo J, Kyritsis AP, et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 1996;56:694-699.
26. Gomez-Manzano C, Fueyo J, Kyritsis AP, et al. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Inst Cancer 1997;14:1036-1044.
27. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
28. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80: 293-299.
29. Ruan S, Okcu MF, Pen PJ, et al. Overexpressed WAF1/Cip1 render glioblastoma cells resistant to chemotherapy agents, 1,3 bis (2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res 1998;58:1538-1543.
30. Jung J-M, Bruner JM, Ruan S, et al. Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene 1995;11: 2021-2028.
31. Chou D, Miyashita T, Mohrenweiser HW, et al. The bax gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet 1996;88: 136-140.
32. Alderson IM, Castleberg RL, Griffith RH, Louis DN, Henson JW. Human gliomas with wild-type p53 express bcl-2. Cancer Res 1995;55:909-1001.
33. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.
34. Serrano M, Lee H-W, Chin L, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
35. Jen J, Harper JW, Bigner SH, et al. Deletion of p 16 and p15 genes in brain tumors. Cancer Res 1994;54:6353-6358.
36. Kyritsis AP, Zhang B, Zhang W, et al. Mutations of the p16 gene in gliomas. Oncogene 1996;12:63-67.
37. Costello JF, Berger MS, Huang H-JS, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 1996;56:2405-2410.
38. Fueyo J, Gomez-Manzano C, Bruner JM, et al. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 1996;13:1615-1619.
39. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang H-SS. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 1995;55:1351-1354.
40. Fueyo J, Gomez-Manzano C, Yung WKA, et al. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 1996;12:103-110.
41. Chintala SK, Fueyo J, Gomez-Manzano C, et al. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 1997;15:2049-2057.
42. Sandig V, Brand K, Herwing S, Lukas J, Bartek J, Strauss M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 1997;3: 313-319.
43. Henson JW, Schnitker BL, Correa KM, et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 1994;36:714-721.
44. Fueyo J, Gomez-Manzano C, Yung WKA, et al. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 1998;50:1307-1315.
45. Fueyo J, Gomez-Manzano C, Yung WKA, et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 1998;4:685-690.
46. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 1997;275:1943-1946.
47. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-362.
48. Mollenhauer J, Weimann S, Scheurlen W, et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumors. Nat Genet 1997;17:32-39.
49. Nakamura H, Yoshida M, Tsuiki H, et al. Identification of a human homologue of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region. Oncogene 1997;16:1009-1019.